Laurus Labs Ltd.Q2 revenue ₹2,206 Cr, EBITDA margin 34.5%, CDMO +86%

Laurus Labs' Q2 FY27 call, held on 29 October 2026, reported a record quarter: revenue of ₹2,206 crore, EBITDA of ₹762 crore at a 34.5% margin, up 2.7 points on the quarter, and profit after tax of ₹441 crore.

Small molecule CDMO sales rose 86% to ₹875 crore, and affordable medicines grew 15% to ₹1,302 crore. First-half income grew 31% to ₹4,233 crore, ROCE reached 22.5% against 17.7% in FY26, and net debt to EBITDA fell to about 1.0x. The company commissioned a commercial-scale peptide block with over 16,000 liters of solid-phase volume, and agreed to buy a 60% stake in Canada's Galenvs Sciences and a stake in peptide resin maker SI & C Resins.

Laurus Bio sales were only ₹64 crore in the half, with commercial supply from its new fermentation facility expected from Q1 FY28. Management reaffirmed ₹3,000 crore of capex over FY27 and FY28, expects peptide commercial revenue around 2029 and stands by gross margin above 60% and EBITDA margin above 30%.